These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11698713)

  • 21. Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients.
    Hasson H; Gianotti N; Danise A; Seminari E; Boeri E; Nozza S; Castagna A; Lazzarin A
    AIDS; 2004 Jan; 18(1):123-7. PubMed ID: 15090838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amprenavir study results released.
    AIDS Patient Care STDS; 1999 Dec; 13(12):754. PubMed ID: 10743545
    [No Abstract]   [Full Text] [Related]  

  • 23. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.
    Reekie J; Reiss P; Ledergerber B; Sedlacek D; Parczewski M; Gatell J; Katlama C; Fätkenheuer G; Lundgren JD; Mocroft A;
    HIV Med; 2011 May; 12(5):259-68. PubMed ID: 20812948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with lopinavir/ritonavir in heavily pretreated subjects failing multiple antiretroviral regimens in clinical practice.
    Romano L; Peduzzi C; Venturi G; Di Pietro M; Carli T; Corsi P; Gonnelli A; Valensin PE; Zazzi M
    J Acquir Immune Defic Syndr; 2002 Aug; 30(5):533-5. PubMed ID: 12154345
    [No Abstract]   [Full Text] [Related]  

  • 25. [Nevirapine (Viramune): a new HIV inhibitor].
    De Wit S; Sternon J; Clumeck N
    Rev Med Brux; 1999 Apr; 20(2):95-9. PubMed ID: 10335104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.
    De Luca M; Miccinesi G; Chiappini E; Zappa M; Galli L; De Martino M
    Int J Immunopathol Pharmacol; 2005; 18(4):729-35. PubMed ID: 16388722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy.
    Barreiro PM; Dona MC; Castilla J; Soriano V
    AIDS; 1999 Mar; 13(4):525-6. PubMed ID: 10197384
    [No Abstract]   [Full Text] [Related]  

  • 28. First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients.
    Manfredi R; Calza L; Chiodo F
    AIDS; 2004 Nov; 18(17):2331-3. PubMed ID: 15577549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
    HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results.
    Raguin G; Poizat G; Morand-Joubert L; Taburet AM; Le Tiec C; Clavel F; Chêne G; Girard PM;
    AIDS; 2007 Jan; 21(2):241-3. PubMed ID: 17197818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
    Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A
    J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
    Benson CA; Deeks SG; Brun SC; Gulick RM; Eron JJ; Kessler HA; Murphy RL; Hicks C; King M; Wheeler D; Feinberg J; Stryker R; Sax PE; Riddler S; Thompson M; Real K; Hsu A; Kempf D; Japour AJ; Sun E
    J Infect Dis; 2002 Mar; 185(5):599-607. PubMed ID: 11865416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.
    Dailly E; Raffi F; Biron C; Allavena C; Jolliet P
    Fundam Clin Pharmacol; 2008 Feb; 22(1):101-4. PubMed ID: 18251726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
    MMW Fortschr Med; 2003 Dec; 145(50):61. PubMed ID: 14963981
    [No Abstract]   [Full Text] [Related]  

  • 35. A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy.
    Harris M; Durakovic C; Rae S; Raboud J; Fransen S; Shillington A; Conway B; Montaner JS
    J Infect Dis; 1998 Jun; 177(6):1514-20. PubMed ID: 9607828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
    Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
    Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unfavourable interaction of amprenavir and lopinavir in combination with ritonavir?
    Mauss S; Schmutz G; Kuschak D
    AIDS; 2002 Jan; 16(2):296-7. PubMed ID: 11807318
    [No Abstract]   [Full Text] [Related]  

  • 38. High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response.
    Podzamczer D; King MS; Klein CE; Flexner C; Katlama C; Havlir DV; Letendre SL; Eron JJ; Brun SC; Bernstein B
    HIV Clin Trials; 2007; 8(4):193-204. PubMed ID: 17720659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protease inhibitor-sparing regimens: new evidence strengthens position.
    Moyle GJ
    J Acquir Immune Defic Syndr; 2003 Jun; 33 Suppl 1():S17-25; quiz S26-8. PubMed ID: 12946062
    [No Abstract]   [Full Text] [Related]  

  • 40. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
    Kashuba AD; Tierney C; Downey GF; Acosta EP; Vergis EN; Klingman K; Mellors JW; Eshleman SH; Scott TR; Collier AC
    AIDS; 2005 Jan; 19(2):145-52. PubMed ID: 15668539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.